4LE DELEY M C, GU1NEBRET1ERE J M, GENTET J C, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients[J]. Eur J Cancer, 2007,43 (4) :752-761.
5BACCI G, MERCURI M, BRICCOLI A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions [J]. Cancer, 1997, 79(2) :245-254.
6ZALUPSKI M M, RANKIN C, RYAN J R, et al. Adjuvant therapy of osteosarcoma-A phase Ⅱ trial: Southwest Oncology Group study 9139[J]. Cancer, 2004, 100(4) : 818-825.
7PATEL S J, LYNCHJW J R, JOHNSON T, et al. Dose-intense inosfamide/doxorubicin/c isplatin based chemotherapy for osteosarcoma in adults [J]. Am J Clin Oncol, 2002, 25 ( 5 ) :489-495.
8BACCI G, BRICCOLI A, ROCCA M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with eisplatin, doxorubiein, and a high dose of methotrexate and ifosfamide[J]. Ann Oncol, 2003, 14(7) :1126-1134.
9CONRMIER J N, PATEL S R, HERZOG C E. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatmentrelated toxicity in 43 patients with sarcoma[ J]. Cancer, 2001,92 (6) :1550-1555.
10MCVAY J I, WOOD A M. Suspected ifosfamide-induced neurotoxicity[J]. Pharmacotherapy, 1999, 19(12):1450-1455.
